|
|
Vaccine Detail
|
Bcl-Xl_42-CAF09b Vaccine |
| Vaccine Information |
- Vaccine Name: Bcl-Xl_42-CAF09b Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Subunit vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: B-cell lymphoma extra large protein (bcl-xl_42) (NCT03412786)
- Immunization Route: Intramuscular injection (i.m.)
- Description: The vaccine is made up of Bcl-xl_42 and the adjuvant CAF09b for patients with hormone-sensitive Prostate Cancer (PC) and lymph node metastases. B-cell lymphoma extra large protein (Bcl-xl) protein plays a vital role in the cancer cell's ability to avoid programmed cell death (apoptosis) and is upregulated in a variety of cancerous diseases, Bcl-xl_42 is a peptide fragment of the full protein and can lead to the death of cancer cells. CAF09b improves the activation of the immune system. (NCT03412786)
|
| Host Response |
|
|
| References |
NCT03412786: Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases [https://clinicaltrials.gov/study/NCT03412786]
|
|
